Novartis Vaccines and Diagnostics Srl

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Sclavo Spa

Chiron S.r.l.

Glaxosmithkline Biologicals Sa

Gsk Vaccines S.r.l.

Giuliano Bensi

Guido Grandi

Cesira Galeotti

John Telford

Maria Scarselli

Immaculada Margarit Y Ros

Catherine Greer

Emiliano Chiarot

Roberto Petracca

Daniela Tornese Buonamassa

Nathalie Norais

Sergio Abrignani

Giovanni Raugei

Manuel J Rodriguez Ortega

Alessio Zippo

Maria L Melli

Emanuela Palla

Sabrina Capo

Manuel Rodriguez Ortega

Andrea Manetti

Imma Margarit Y Ros

The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.

[object Object]

Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection againstare useful in vaccine compositions to induce protection against

Mutant forms of streptolysin O

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.

Method for producing yeast expressed HPV types 6 and 16 capsid proteins

Group A streptococcal (GAS) antigens useful for providing immunity againstinfection.

Cytotoxic T-cell epitopes fromproteins have been empirically determined. The epitopes from correspondingproteins have also been identified, and some of these are identical to those fromThe empirical method showed that algorithmic prediction was inadequate. The epitopes are useful for immunisation and/or diagnosis.

Immunogenic compositions for streptococcus pyogenes

The invention provides a nodavirus RNA1 molecule modified to include a heterologous insertion which is downstream of its replicase ORF and, preferably, its B2 ORF. The insertion preferably comprises one or more protein-coding regions. The modified RNA1 may be packaged in a VLP, such as a papillomavirus VLP. The small size of nodavirus RNA1 makes it ideal for HPV packaging.

Modified nodavirus RNA for gene delivery

Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production conformational antibodies against both L1 proteins upon administration to mice.

The invention provides an expression and secretion vector in yeasts which is useful for preparing heterologous proteins, comprising a synthetic oligonucleotide which directs the secretion of the heterologous protein wherein the synthetic oligonucleotide is positioned between the inducible hybrid promoter GAL-CYC and a multiple-site polylinker followed by the signals of transcription termination recognized by the RNA polymerase of the yeasts. The invention includes a hybrid plasmid obtained by cloning in one of the restriction sites of the polylinker of the vector, the DNA sequence which codes for a heterologous protein. A process is also described for the preparation of heterologous proteins which comprises cultivating in a suitable culture medium a yeast transformed with the hybrid plasmid and recovering from the culture medium the resulting heterologous proteins. The recovered proteins include hormones, lymphokines, viral antigens or immunogens useful in the therapeutical and diagnostic field.

Expression and secretion vector in yeasts, useful for preparing

Growing community of inventors

Florence, Italy

Giuliano Bensi